These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19361869)

  • 1. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.
    Kato M; Zanardi R; Rossini D; De Ronchi D; Okugawa G; Kinoshita T; Colombo C; Serretti A
    Psychiatry Res; 2009 May; 167(1-2):97-105. PubMed ID: 19361869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.
    Kishi T; Yoshimura R; Kitajima T; Okochi T; Okumura T; Tsunoka T; Yamanouchi Y; Kinoshita Y; Kawashima K; Naitoh H; Nakamura J; Ozaki N; Iwata N
    Neuromolecular Med; 2010 Sep; 12(3):237-42. PubMed ID: 19937159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders.
    Serretti A; Mandelli L; Lorenzi C; Pirovano A; Olgiati P; Colombo C; Smeraldi E
    Psychiatry Res; 2007 Jan; 149(1-3):185-93. PubMed ID: 17157919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder.
    Kishi T; Ichinose H; Yoshimura R; Fukuo Y; Kitajima T; Inada T; Kunugi H; Kato T; Yoshikawa T; Ujike H; Musso GM; Umene-Nakano W; Nakamura J; Ozaki N; Iwata N
    J Affect Disord; 2012 Dec; 142(1-3):315-22. PubMed ID: 22770721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Okumura T; Tsunoka T; Ozaki N; Iwata N
    Neuromolecular Med; 2009; 11(2):53-7. PubMed ID: 19347611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.
    Paddock S; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ
    Am J Psychiatry; 2007 Aug; 164(8):1181-8. PubMed ID: 17671280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.
    Qesseveur G; Petit AC; Nguyen HT; Dahan L; Colle R; Rotenberg S; Seif I; Robert P; David D; Guilloux JP; Gardier AM; Verstuyft C; Becquemont L; Corruble E; Guiard BP
    Neuropharmacology; 2016 Jun; 105():142-153. PubMed ID: 26764241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT2A receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study.
    Liang CS; Ho PS; Chiang KT; Su HC
    J Sex Med; 2012 Aug; 9(8):2009-16. PubMed ID: 22612784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.
    Kato M; Fukuda T; Serretti A; Wakeno M; Okugawa G; Ikenaga Y; Hosoi Y; Takekita Y; Mandelli L; Azuma J; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):398-404. PubMed ID: 17913323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Azuma J; Kinoshita T; Serretti A
    Neuropsychobiology; 2007; 56(4):167-71. PubMed ID: 18332644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
    Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
    J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors.
    Serretti A; Zanardi R; Cusin C; Rossini D; Lilli R; Lorenzi C; Lattuada E; Smeraldi E
    Psychiatry Res; 2001 Nov; 104(3):195-203. PubMed ID: 11728608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder.
    Sunada N; Takekita Y; Nonen S; Wakeno M; Koshikawa Y; Ogata H; Kinoshita T; Kato M
    Neuropsychobiology; 2019; 78(3):136-144. PubMed ID: 31189175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.